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higher weight (72.7kg) than no lower extremity OA group (0.298 
kg/kg weight and 65.5kg respectively; p=<0.05). In this sample, 
baseline lower strength (RR=0.02) and higher weight (RR=1.03 
per kg) were independently associated with greater risk of dis- 
ability transitions (p < 0.05). Baseline lower strength was also a 
risk factor for incident knee pain over 36 months (p < 0.01). 
Conclusions: Lower extremity OA, lower knee extensor strength, 
and higher weight increase the risk of disability transitions ub- 
stantially over 36 months in high functioning older women, 
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EVALUATION OF SAFETY AND EFFICACY OF HYLAN GF-20 
IN KNEE OSTEOARTHRITIS WITH CHONDROCALClNOSIS 
Virginie Legre, Thao Pham, Pierre Lafforgue 
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France 
Background: Pseudogout attacks following hyaluronan and 
hylan intra-articular injections have been reported, suggesting 
that viscosupplementation should be avoided in calcium 
pyrophosphate dihydrate (CPPD) deposition disease. In a previ- 
ous prospective study, we evaluated sodium hyaluronate 
(Hyalgan) injections in a series of osteoarthritis (OA) of the knee 
with chondrocalcinosis, and found no instance of acute 
pyrophosphate arthritis (Daumen-Legre ta!, Arthritis Rheum 
1999, [abstr] 9: Si 58). Only mild local reactions were recorded 
after 7.3% of the injections. No data is yet available concerning 
hylan injections in CPPD disease. 
Objective: To evaluate the occurrence of adverse events and 
the efficacy of a Hylan GF-20 (Synvisc) course in patients with 
both knee OA and CPPD disease. 
Methods: 24 knees in 21 patients with painful osteoarthritis 
(ACR criteria) and radiological typical chondrocalcinosis, were 
given three intraarticular injections of Hylan GF-20 at 1-week 
intervals, with a definite injection technique, in a 6- months fol- 
low-up prospective open study. The occurrence of adverse 
effects and clinical outcome (pain visual analog scale (VAS), func- 
tional Lequesne index, WOMAC) were evaluated at baseline, final 
injection, week 2 and week 22. 
Results: No acute pyrophosphate arthritis occurred in this 
series. 8 transient knee pain or swelling reactions (severe in one 
case) were recorded after the 72 Hylan injections (11%) in 7 
patients, without discontinuation of the treatment. Significant 
improvement of pain and function (p<0.001) was found at evalua- 
tion of 21 knees (3 patients lost), using a Wilcoxon test. 
Conclusion: Hylan GF-20 injections did not induce pseudogout 
attacks in OA patients with CPPD deposits. Transient non crystal 
induced local reactions occurred in 29% of patients. This tudy 
also suggests the beneficial clinical effects of Hylan in knee 
osteoarthritis with chondrocalcinosis. 
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SURVEY ON 10 000 PATIENTS 
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P Coste 4, M Rossignol 5 
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Osteoarthritis (OA) is a public health problem in many countries, 
but its clinical burden is not precisely known. This is mainly due 
to its considerable variability and the relative lack of reliable clin- 
ical data in administrative databases. 
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Methods: In 2000, a nation-wide survey of more than 5,000 
physicians, either general practitioners (90.3%) or rheumatolo- 
gists (9.7%), representative of the French medical demography, 
was conducted. Each recruited the first 2 patients consulting for 
hip, knee or hand OA after the onset of the survey. 
Results: Clinical and social information was available for'10412 
OA patients, mean-age 66.2 ±10.2 years, sex ratio (F:M) 1.96. For 
84.5% of them, OA diagnosis was based on both clinical and 
radiographic findings. 88.3% had already consulted their physi- 
cian for an OA problem. 
Joint involved 
OA Duration 
Symptoms 
Hand 
Hip 
Knee 
Polya~icular(< 1 jointinvolved) 
Pain only 
Functional Impairment (FI) only 
Pain and FI 
Pain, FI and swelling 
Mean duration of pain previous month 
Mean number of lares in previous year 
Prosthesis Hip 
prevalence Knee 
7.5% 
13.7% 
31.5% 
47.3% 
9.3±6.8 years 
29.1% 
18.6 % 
39.9% 
8.1% 
15.7±6.6 days 
2.4±0.6 
6.6 % 
3.9 % 
Conclusion: This study provides a nationally representative 
description of patients consulting for CA in France. Almost half of 
people consulting for OA have polyarticular thritis. On average, 
patients suffered from OA 15 days within the 30 days preceding 
the visit, and experience between 2 and 3 flares in the year before 
the survey. OA patients who consult seem to have very sympto- 
matic forms of OA. 
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MANAGEMENT OF OSTEOARTHRITIS (OA) WITH PATIENT- 
ADMINISTERED ASSESSMENT TOOLS AND/OR UNSUPER- 
VISED HOME-BASED EXERCISES PROGRAM. 
A 2x2 FACTORIAL DESIGN CLUSTER RANDOMIZED 
CONTROLLED TRIAL 
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Objectives: To evaluate the short term symptomatic efficacy of 
patient-administered assessment tools (-Fools) and home non- 
supervised exercises programs (Exercises) alone or in combina- 
tion in OA patients. 
Methods: 
Design. A 24 weeks open cluster randomized controlled-trial with 
a factorial design. 
Setting. French rheumatotogists (n=867) were assigned to 4 
groups: Tools (n=220), Exercises (n=213), Tools + Exercises 
(n=213), no intervention (n=221). Patients. Each r eumatologist 
had to enroll 4 painful OA patients (knee OA: 3, hip OA: 1). 
Interventions. 1) Tools: weekly diary including the record of pain 
and disabling activities 2) Home-based exercises programs with 
the aid of videotape and booklet, performed daily. Concomitant 
therapy. All patients received rofecoxib (12.5 mg or 25 mg QD). 
Outcome variables. 
Pain (VAS 0-100), WOMAC function subscale (0--t00), patient 
assessment of the quality of care (0-100). 
Results: Overall 2957 patients (2216 knee OA, 741 hip OA) were 
included. After 24 weeks, both pain and function improved (-17 + 
27, -20 ± 29, -15 ± 27, -19 ± 29) and (-11 + 19 -12 + 19, -10 + 
19, -11 ± 20) in the different groups (Tools, Exercises, Tools + 
Exercises and no intervention groups respectively), without sta- 
tistical significant difference between groups. Patient's assess- 
ment of rheumatologist implication to preserve their activity was 
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77.7 and 81.3 in the exercises groups and 63.4 and 63.5 in the 
other groups. 
Conclusion; Although the patient's assessment was in favor of 
the exercises programs, this study failed to demonstrate short 
term symptomatic effect of the two non pharmacologic evaluated 
treatments in OA patients concomitantly receiving Cox-2 
inhibitors. 
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OSTEOARTHRITIS AND JOINT HYPERMOBILITY 
SYNDROME IN CROSS -EXAMINATIONS 
Shakulashvili N.A., Chikhladze H.E., Akhvlediani R.R 
Rheumatology Centre, Tbilisi, Georgia 
Aim: The aim of the study was to compare the frequency of avail- 
ability and peculiarities of osteoarthritis (OA) in'joint hypermobili- 
ty syndrome (JHS) and without it with that of JHS in OA and with- 
out it. 
Methods: In 813 patients with JHS and in 980 persons without 
it, the frequence of OA occurrence was studied according to the 
criteria of Benevolenskaya L.Y. and Bredovsky M.M. (1986). In 
695 patients with significant OA from another population and 
1153 healthy control persons, the frequence of JHS occurrence 
was studied according to the criteria of C. Carter and G. 
Wilkinson (1964) in R Beighton and E Horran's modification 
(1970). Risk Index (RI) was determined by V. V. Dvoirin's method 
(1975). 
Results: OA in JHS appeared to be available 4 times as much 
(32.7%) than without JHS (8.3%), while JHS is revealed 2,5 times 
as much in patients with OA (28.2%) than without it (13.5%). The 
correlation of men to women in he both groups was 1:4. 
in patients with JHS we mainly reveal generalized OA (96.6%), 
much more rarely peripheral joint(1.5%) and spine (1.9%) OA 
while in the group of persons without JHS, peripheral joint OA is 
predominant (70.7%). 
Results 
Interdependence and correlation between OA and JHS is evident, 
since 1) JHS increases the risk of OA development 3 times as 
much (OR=3) while that of generalized OA - 7 times; 2) Among all 
the patients with OA, JHS is observable 2,5 times as much than 
in the control group. 
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SIMILAR PAIN BUT WORSE FUNCTION COMPARED WITH 
MATCHED CONTROLS 3-5 YEARS AFTER TOTAL HIP 
REPLACEMENT FOR OA 
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Departments of Orthopedics, Lund University Hospital 1, 
Spenshult Hospital, Halmstad 2, Sweden 
Objectives: To investigate in a prospective follow up study the 
long term (3-5 year) patient relevant outcomes after total hip 
replacement in comparison with an age, sex and municipality 
matched group of controls. 
Methods: 219 patients (120 women) with a mean age at time of 
surgery of 68 years (50-92) were included in the study. All patients 
had a primary unilateral total hip replacement performed because 
of primary osteoarthritis. The group of controls consisted of 117 
individuals without hip complaints, matched by age, sex and 
municipality. 
The patients and the controls were investigated with SF-36 and 
WOMAC, scored on a scale 0-100, worst to best, preoperatively 
3, 6, 12 months and 3-5 years postoperatively. 
Results: In all, 198 (106 women, mean age 71) of the patients 
participated at the 3-5 year follow-up; 8 had died during the fol- 
low-up period and 13 abstained; 83 (46 women, mean age 71) of 
the controls participated; 8 had died and 26 abstained. There 
were no differences between the patients and the controls in the 
SF-36 subscales except physical function (PF) where the controls 
scored significantly better (71 vs. 59 p=< 0.0001). There were sta- 
tistically significant differences in the WOMAC pain and function. 
The controls showed less pain (87 vs. 82, p=O.006) and better 
function (84 vs. 74, p=>0.0001) than the patients. The differences 
in pain, however, of doubtful clinical significance. 
Conclusion: This prospective study has shown that 3-5 years 
after total hip replacement the patients experience similar pain 
but worse function compared to matched controls followed at the 
same intervals. However, the health related quality of life in gen- 
eral was the same. 
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THE RELEVANCE OF VIRTUE ETHICS TO PATIENTS 
WITH CHRONIC OSTEOARTHRITIS 
T Swift, P Dieppe 
MRC HSRC and Centre for Ethics in Medicine, Bristol, UK 
Aim: To explore the relevance of virtue ethics (VE) to patients 
with chronic osteoarthritis (OA). 
Methods: An Aristotolian concept was used to construct a 
guide to in-depth, semi-structured interviews, carried out with 
five patients with chronic osteoarthritis. They were tape-record- 
ed, transcribed and analysed (using interpretative phenomeno- 
logical analysis) for themes relating to possible virtues needed 
to allow a person to thrive in spite of having chronic, painful and 
disabling OA. 
Results: The five patients ranged in age from 63-89, and all had 
large joint OA (hip and or knee disease) of 2-16 years duration. 
Five main themes emerged from the interview transcripts: 
strength (determination), realism (gaining a realistic understand- 
ing of the condition), gratitude (appropriate gratitude for relative 
good fortune), identity (feelings of self-worth) and insight (main- 
taining interests and relationships of importance). Each of these 
themes fit well with existing concepts of virtues within philo- 
sophical literature, from Aristotle and St Thomas Aquinus, to the 
modern theories of Maclntyre. The emphasis that VE theory 
places on the development of virtues throughout the course of 
life, and their importance to our response to adversity seemed 
to be mirrored by the experiences of our patients. 
Conclusions: People with chronic pain and disability respond to 
their condition in a variety of ways, with different outcomes. This 
is generally described in terms of coping theory or quality of life. 
Virtue ethical theory can be applied descriptively to the experi- 
ence of people with chronic OA, and may help us (and them) 
understand their different coping strategies and their quality of 
life in the face of arthritis. 
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MEASUREMENT OF THE OSTEOARTHRITIC KNEE 
JOINT SPACE WIDTH 
E. Vignon, H. Favret, P. Mathieu, T. Conrozier, M. Piperno. 
C/aude Bernard Universi~ Lyon, France 
Objective: (1) To evaluate various methods of measurement of 
the femorotibial joint space width; (2) to evaluate the impact of 
the quality of knee radiography in the assessment of joint space 
narrowing progression. 
Methods: A total of 58 patients with femorotibial osteoarthritis 
(ACR criteria) were radiographed both in the standard position 
